For an adult with an acute gout flare, when is indomethacin preferred over meloxicam and vice versa, considering dosing regimens, efficacy, and gastrointestinal or renal safety?

Indomethacin vs Meloxicam in Acute Gout

Neither indomethacin nor meloxicam should be your first-line choice for acute gout—corticosteroids are preferred due to superior safety with equivalent efficacy. When NSAIDs are necessary, meloxicam offers better gastrointestinal tolerability than indomethacin without sacrificing pain relief, making it the safer NSAID option. 1, 2, 3

First-Line Treatment: Corticosteroids Over All NSAIDs

The American College of Physicians strongly recommends oral corticosteroids as first-line therapy for acute gout flares. 1, 2 This recommendation is based on high-quality evidence showing:

• Equivalent pain relief to NSAIDs (including both indomethacin and meloxicam), with mean pain reduction of approximately 44-46 mm on a 100-mm visual analog scale at 90 hours 2, 4
• Significantly fewer adverse events, particularly gastrointestinal complications 1, 2, 4
• Prednisolone 35 mg daily for 5 days (no taper needed) achieves complete symptom resolution in most patients 2

When NSAIDs Are Necessary: Meloxicam Over Indomethacin

If corticosteroids are contraindicated or refused, meloxicam is preferred over indomethacin for the following reasons:

Superior Gastrointestinal Safety Profile

• Meloxicam demonstrates sixfold less inhibition of gastric mucosal prostaglandin E synthesis compared to indomethacin (IC50 11.8 μM vs 1.8 μM), directly translating to reduced gastric injury risk 3
• Meloxicam is COX-2 selective (COX-2/COX-1 ratio of 0.2) while indomethacin is non-selective (ratio 0.9), sparing the constitutive COX-1 enzyme that protects gastric mucosa 3, 5
• Clinical trials confirm meloxicam causes significantly fewer gastrointestinal adverse events than non-selective NSAIDs like indomethacin 6, 7

Equivalent Analgesic Efficacy

• No NSAID has proven superior to another for pain relief in acute gout 2, 8, 6
• Moderate-certainty evidence shows COX-2 selective inhibitors (including meloxicam) and non-selective NSAIDs produce equivalent pain reduction, inflammation control, and treatment success rates 6
• The traditional preference for indomethacin is not evidence-based; it persists only from historical use patterns 2

Renal and Cardiovascular Safety

• Meloxicam at therapeutic doses (7.5 mg daily) does not inhibit platelet function or thromboxane formation, unlike indomethacin which causes near-complete platelet inhibition 5
• Meloxicam shows minimal effects on renal prostaglandin synthesis (13% reduction in urinary PGE2) compared to indomethacin (43% reduction), suggesting better preservation of renal function 5

Specific Dosing Regimens

Indomethacin (if used)

• 50 mg three times daily until pain is tolerable, then rapidly taper to cessation 9
• Pain relief typically occurs within 2-4 hours; swelling resolves over 3-5 days 9
• Maximum daily dose: 200 mg 9

Meloxicam (if used)

• 15 mg once daily for acute gout (standard anti-inflammatory dose)
• Simpler once-daily dosing improves adherence compared to indomethacin's three-times-daily regimen

Absolute Contraindications to Both NSAIDs

Do not use indomethacin or meloxicam in patients with: 2

• Chronic kidney disease (stage ≥3; CrCl <60 mL/min)
• Congestive heart failure
• Cirrhosis
• Active or recent gastrointestinal bleeding
• Peptic ulcer disease
• Concurrent anticoagulation therapy (elevated bleeding risk)

In these populations, use prednisolone 35 mg daily for 5 days instead. 2

Treatment Algorithm for Acute Gout

1. First choice: Prednisolone 35 mg once daily for 5 days (or 30-50 mg daily with 10-day taper if longer course preferred) 2

2. If corticosteroids contraindicated: Low-dose colchicine (1.2 mg loading dose, then 0.6 mg one hour later) only if started within 36 hours of symptom onset 2

3. If both corticosteroids and colchicine unsuitable: Use an NSAID at full anti-inflammatory dose, preferring meloxicam 15 mg daily over indomethacin 50 mg three times daily due to superior safety profile 2, 3, 5

4. Continue therapy at full dose until complete symptom resolution (typically 7-14 days) 2

Common Clinical Pitfalls

• Reflexively prescribing indomethacin as "the gout drug" is outdated practice not supported by comparative efficacy data 2, 6
• Using NSAIDs in patients with renal impairment can precipitate acute kidney injury; always check creatinine clearance before prescribing 2
• Stopping treatment too early leads to rebound flares; maintain full-dose therapy until complete resolution 2
• Combining NSAIDs with anticoagulants dramatically increases bleeding risk; switch to corticosteroids 2

Special Populations

Diabetes

• Short-course corticosteroids cause transient hyperglycemia but remain safer than NSAIDs in diabetic patients with any degree of nephropathy 2
• Temporary adjustment of diabetes medications manages the glucose elevation 2

Cardiovascular Disease

• Corticosteroids are preferred over NSAIDs, which may worsen heart failure and increase cardiovascular events 2

Elderly Patients

• Advancing age increases NSAID adverse event risk; use lower doses and shorter durations, or preferentially use corticosteroids 9